HC Wainwright Has Bullish Estimate for Alumis Q1 Earnings

Alumis Inc. (NASDAQ:ALMS - Free Report) - Research analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for Alumis in a research report issued on Tuesday, April 22nd. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($1.03) per share for the quarter, up from their prior estimate of ($1.07). HC Wainwright currently has a "Buy" rating and a $14.00 target price on the stock. The consensus estimate for Alumis' current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis' Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.74) EPS and FY2025 earnings at ($3.22) EPS.

A number of other equities research analysts have also weighed in on ALMS. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a report on Thursday, March 20th. Oppenheimer began coverage on Alumis in a report on Thursday, January 30th. They issued an "outperform" rating and a $32.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Alumis has an average rating of "Buy" and an average target price of $25.86.

Alumis Stock Up 9.7 %

NASDAQ:ALMS traded up $0.40 during mid-day trading on Thursday, hitting $4.52. The stock had a trading volume of 154,665 shares, compared to its average volume of 315,654. Alumis has a twelve month low of $3.18 and a twelve month high of $13.53. The stock has a 50-day simple moving average of $5.48 and a two-hundred day simple moving average of $7.60.

Insider Buying and Selling at Alumis

In other Alumis news, Director Alan Colowick purchased 16,104 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were purchased at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the purchase, the director now directly owns 16,104 shares in the company, valued at $112,244.88. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martin Babler acquired 15,650 shares of the business's stock in a transaction on Tuesday, April 1st. The stock was acquired at an average price of $6.44 per share, with a total value of $100,786.00. Following the transaction, the chief executive officer now directly owns 106,454 shares of the company's stock, valued at $685,563.76. This represents a 17.23 % increase in their position. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its holdings in shares of Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company's stock worth $102,000 after acquiring an additional 2,949 shares during the period. Wells Fargo & Company MN raised its stake in shares of Alumis by 77.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company's stock worth $69,000 after buying an additional 3,823 shares during the last quarter. Northern Trust Corp boosted its position in shares of Alumis by 4.3% in the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company's stock worth $875,000 after buying an additional 4,587 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Alumis by 4.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 113,401 shares of the company's stock valued at $891,000 after acquiring an additional 4,808 shares during the last quarter. Finally, Barclays PLC increased its holdings in Alumis by 33.9% during the 4th quarter. Barclays PLC now owns 24,581 shares of the company's stock valued at $193,000 after acquiring an additional 6,221 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.